Eplerenone alleviates diabetic cardiomyopathy by modulating ER stress, oxidative stress, and NLRP3 inflammasome activation

Authors:

Abstract
Objectives Diabetic cardiomyopathy (DCM) is a serious diabetes complication of the heart characterized by changes in the structure and function of the organ. It involves oxidative stress, inflammation, and Endoplasmic Reticulum (ER) stress in its pathogenesis. This study investigates how Eplerenone (EPL), a selective mineralocorticoid receptor blocker, can treat these complications in diabetic rats. Methods A total of 32 male Wistar rats were divided into diabetic and control groups after induction of diabetes using Nicotinamide and Streptozotocin. Eplerenone was given at 100 mg/kg/day for 8 weeks. Blood glucose levels, troponin levels, markers for oxidative stress, markers for ER stress and inflammation were assessed. Results Eplerenone treatment significantly improved oxidative stress indicators by increasing GSH and SOD levels and lowering MDA concentrations. Furthermore, in diabetic rat hearts, Eplerenone also decreased the content of ER stress markers GRP78 as well as XBP1 together with inflammatory markers IL-1β and NLRP3. Although the serum glucose levels did not change significantly, Eplerenone treatment restored the elevated troponin I levels and showed increased cardiac integrity. Conclusions Eplerenone successfully reduces oxidative stress, ER stress, and inflammation in DCM, indicating its promise as a treatment for diabetes-related complications. More investigation is required to assess Eplerenone’s clinical applicability in diabetic patients.
Funding Information
  • Ahvaz Jundishapur University of Medical Sciences (HLRC-0209)

This publication has 34 references indexed in Scilit: